)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Olema Pharmaceuticals
Olema Pharmaceuticals (OLMA) investor relations material
Olema Pharmaceuticals TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary3 Mar, 2026
Strategic focus and pipeline overview
Focused on transforming care for ER-positive, HER2-negative breast cancer with lead asset palazestrant, a complete estrogen receptor antagonist in pivotal trials OPERA-01 (second/third line, monotherapy) and OPERA-02 (first line, combination with ribociclib).
OPERA-01 readout expected in fall; OPERA-02 enrolling ~1,000 patients, earliest readout in 2028.
Second asset, OP-3136 (KAT6A/B, VII inhibitor), in phase I/II for multiple cancers; first monotherapy data expected Q2.
Palazestrant’s unique properties include high exposure, oral dosing, and strong combinability with targeted agents.
Building a US-focused commercial presence, seeking global partners for ex-US markets.
Clinical data and differentiation
Palazestrant shows superior steady-state exposure and receptor occupancy compared to class peers.
Demonstrated median progression-free survival (PFS) of 7.3 months (ESR1 mutant) and 5.5 months (wild type) in heavily pre-treated populations.
Activity in both ESR1 mutant and wild type populations distinguishes palazestrant from other SERDs.
In post-CDK4/6 setting, median PFS reached 14 months (mutant) and over 9 months (wild type), exceeding other combinations.
OP-3136 aims for improved tolerability over Pfizer’s KAT6 inhibitor by increased selectivity.
Market opportunity and commercial strategy
ER+/HER2- breast cancer represents a multi-billion dollar market: $5B in second/third line, $10B+ in first line, with adjuvant potentially larger.
Duration of treatment is a key driver of market size; significant PFS improvements could double market opportunity.
Potential phase III trial for OP-3136 in 2028; pivotal OPERA-01 readout could enable launch as early as next year.
Ended year with ~$500M cash, supporting execution through multiple data readouts.
OPERA-02: What PFS increase defines success?
OP-3136: How will safety differentiate from Pfizer?
Evaluate 2nd line palazestrant+ribo combo trial
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Olema Pharmaceuticals earnings date
Q4 202513 Mar, 2026
Olema Pharmaceuticals
Next Olema Pharmaceuticals earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Olema Pharmaceuticals, Inc., also known as Olema Oncology, is a clinical-stage biopharmaceutical company that focuses on developing targeted therapies for the treatment of women's cancers. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage